Manage settings
MENU
About this site
In het Nederlands
Home
Researchers
Projects
Organisations
Publications
Contact
Research Explorer
Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.
Researcher
Tim Lammens
Profile
Projects
Publications
Activities
Awards & Distinctions
Results
:
ALL
(
14
)
Order By :
Title (a-z)
Title (a-z)
Chronological by starting year (new to old)
As
Promotor
01 October 2021 → 30 September 2024
Preclinical evaluation of newly identified therapeutic targets in pediatric acute myeloid leukemia
Funding: Funding by bilateral agreement (private and foundations)
01 November 2020 → 31 October 2024
Preclinical study of TARP-directed cellular and nanobody therapy in pediatric AML: improving survival and quality-of-life
Funding: Funding by bilateral agreement (private and foundations)
01 October 2023 → 30 September 2027
Research assignment of Prof. dr. Tim Lammens, framing the ongoing clinical-translational research at the Department of Pediatric Hematology-Oncology and Stem Cell Transplantation
Funding: Funding by bilateral agreement (private and foundations)
16 August 2023 → 16 August 2024
Stichting Me To You : Research Grants Jolien Vanhooren: "Deciphering the role of Nidogen-1 in pediatric acute myeloid leukemia"
Fellow: Jolien Vanhooren
Funding: Funding by bilateral agreement (private and foundations)
01 November 2021 → 31 October 2022
The impact of magnetic particulate matter (mPM) pollution as a contributing factor for development of childhood cancer: an in vitro and in vivo molecular and cellular analysis.
Funding: Funding by bilateral agreement (private and foundations)
As
Copromotor
01 May 2022 → 30 April 2026
A patient derived xenograft (PDX) platform for in vivo evaluation of novel anticancer therapies
Funding: Research Foundation - Flanders (FWO)
01 October 2020 → 23 September 2022
Minimal residual disease targeting in T-cell acute lymphoblastic leukemia
Fellow: Julie Morscio
Funding: Regional and community funding: Special Research Fund
01 October 2022 → 30 September 2023
Preclinical validation of a less toxic variant for paediatric leukemia
Funding: Funding by bilateral agreement (private and foundations)
01 June 2016 → 31 May 2018
Predisposition in a family with two pediatric patients with Hodgkin lymphoma Non-Burkett
Funding: Funding by bilateral agreement (private and foundations)
01 January 2013 → 31 December 2015
The role of non-coding RNA in juvenile myelomonocytic leukemia
Funding: Funding by bilateral agreement (private and foundations)
15 December 2012 → 31 December 2013
The role of non-coding RNA in juvenile myelomonocytic leukemia
Funding: Funding by bilateral agreement (private and foundations)
As
Fellow
01 January 2015 → 31 December 2018
Evaluation of the prognostic value of the leukemic stem cell (LSC) and pre-leukemic hematopoietic stem cell (pre-L HSC) for minimal residual disease monitoring and clinical management of pediatric acute myeloid leukemia patients
Fellows: Tim Lammens
Funding: Funding by bilateral agreement (private and foundations)
01 June 2015 → 30 September 2019
Research Assignment dr. Tim Lammens ihkv the ongoing clinical-translational research at the department of Pediatric Hematology-Oncology and Stem Cell Transplantation
Fellows: Tim Lammens
Funding: Funding by bilateral agreement (private and foundations)
As
Researcher
01 October 2021 → 30 September 2025
The use of a less toxic alternative asparaginase variant to treat metastatic breast cancer
Funding: Regional and community funding: Special Research Fund